Gamida Cell Ltd. (NASDAQ:GMDA) Sees Large Drop in Short Interest

Gamida Cell Ltd. (NASDAQ:GMDAGet Rating) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totalling 2,710,000 shares, a drop of 9.4% from the August 15th total of 2,990,000 shares. Currently, 6.0% of the company’s stock are short sold. Based on an average daily volume of 566,400 shares, the short-interest ratio is presently 4.8 days.

Institutional Trading of Gamida Cell

Institutional investors and hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC grew its position in Gamida Cell by 13.6% during the first quarter. ARK Investment Management LLC now owns 853,501 shares of the company’s stock valued at $3,542,000 after buying an additional 102,432 shares during the period. GSA Capital Partners LLP bought a new position in Gamida Cell during the fourth quarter valued at about $83,000. JPMorgan Chase & Co. grew its position in Gamida Cell by 12.8% during the first quarter. JPMorgan Chase & Co. now owns 731,328 shares of the company’s stock valued at $3,035,000 after buying an additional 83,009 shares during the period. Mariner LLC grew its position in Gamida Cell by 8.3% during the first quarter. Mariner LLC now owns 621,334 shares of the company’s stock valued at $2,579,000 after buying an additional 47,587 shares during the period. Finally, Walleye Capital LLC bought a new position in Gamida Cell during the second quarter valued at about $312,000. Hedge funds and other institutional investors own 41.27% of the company’s stock.

Gamida Cell Stock Performance

GMDA opened at $2.42 on Monday. The company’s fifty day moving average price is $2.41 and its two-hundred day moving average price is $2.67. The company has a market cap of $143.26 million, a price-to-earnings ratio of -1.83 and a beta of 1.45. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 9.15. Gamida Cell has a 1-year low of $1.48 and a 1-year high of $4.72.

Gamida Cell (NASDAQ:GMDAGet Rating) last announced its earnings results on Monday, August 15th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). During the same quarter in the previous year, the company posted ($0.42) earnings per share. On average, analysts expect that Gamida Cell will post -1.25 EPS for the current fiscal year.

Analysts Set New Price Targets

GMDA has been the subject of several research analyst reports. JMP Securities reaffirmed a “buy” rating and set a $17.00 target price on shares of Gamida Cell in a report on Thursday, June 2nd. Piper Sandler boosted their target price on shares of Gamida Cell from $6.00 to $8.00 in a research report on Monday, August 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $14.17.

Gamida Cell Company Profile

(Get Rating)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.

Featured Articles

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.